Publication | Open Access

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapyOncologyRadiation OncologyRefractory Multiple MyelomaHealth Sciences